Skip to main content
. 2013 Oct 8;19(1):334–345. doi: 10.2119/molmed.2013.00122

Figure 5.

Figure 5

ARA 290 treatment improves the BPI pain interference score. (A) Weekly pain interference scores significantly decline over the 4 wks of daily dosing for the ARA 290 compared with the placebo group. (B) A proportional responder display illustrates that the ARA 290 group responded to a larger extent at all levels of improvement.